Product Description
Mechanisms of Action: CAR-T,CD19,BCMA
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Essen Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for EB-BH2024-2](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Sjogren's Syndrome|Myositis|Granulomatosis with Polyangiitis|Microscopic Polyangiitis|ANCA Vasculitis|Scleroderma, General|Systemic Vasculitis|Scleroderma, Systemic|Lupus Erythematosus, Systemic|Lupus Vasculitis|Lupus Nephritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BAH242 | P2 |
Not yet recruiting |
Lupus Vasculitis|Systemic Vasculitis|ANCA Vasculitis|Scleroderma, General|Lupus Nephritis|Lupus Erythematosus, Systemic|Myositis|Sjogren's Syndrome|Scleroderma, Systemic|Microscopic Polyangiitis|Granulomatosis with Polyangiitis |
2025-12-10 |